Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

Pfizer Inc. abruptly ended a key hemophilia A gene therapy collaboration with Sangamo Therapeutics Inc., sending the East Bay biotech company's stock sharply lower as its partnership options thinned.

Pfizer’s research partnership with Sangamo Therapeutics produced a hemophilia A gene therapy that reached FDA discussions about a regulatory submission. That’s as far as the alliance will go.

Sangamo chief executive Sandy Macrae has said the company is "surprised and extremely disappointed" by Pfizer's decision to hand back rights to its experimental gene therapy for haemophilia A ...

Pfizer has abandoned development of a hemophilia A gene therapy it licensed from Sangamo Therapeutics, a move that could imperil Sangamo’s future. It’s a sudden turnabout for Pfizer ...

(Reuters) -Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development agreement, sending its shares down nearly 64% in extended trade.

Sangamo also noted it remains committed to advancing its therapy for Fabry disease, aiming to submit it for regulatory approval in the latter half of 2025. Barclays (LON:BARC) analysts said Pfizer ...

Sangamo faces steep drop after Pfizer ends partnership, raising concerns about its hemophilia therapy's future ...

Sangamo Therapeutics Inc.’s stock tumbled 56% on Tuesday for its second-biggest one-day percentage decline ever, after Pfizer Inc. terminated a hemophilia A gene-therapy partnership.

Sangamo intends to explore all options to advance the program, including seeking a potential new collaboration partner. Pfizer has indicated to Sangamo that this termination reflects its decision ...

16:28 EST Sangamo (SGMO) down 31% at $1.61 after Pfizer decision to terminate collaboration Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top ...

Dec 30 (Reuters) - Sangamo Therapeutics (SGMO.O), opens new tab said on Monday that partner Pfizer (PFE.N), opens new tab has terminated their hemophilia A gene therapy co-development agreement ...